| |
American Wrongful Death Law Report
MEDICAL MALPRACTICE IN THE
DIAGNOSIS AND TREATMENT OF PULMONARY EMBOLISM
By Attorney J. Whitfield Larrabee
The Need for Prompt Diagnosis
The failure of doctors to properly diagnose
and treat pulmonary embolism is a leading cause of unnecessary
death in the United States.1
Scientists estimate that as many as 60,000 Americans
die annually as a result of the failure to properly
diagnose pulmonary embolism. More Americans presently
die of pulmonary embolism than die of breast cancer.
Because it is a common and lethal condition, the established
'standard of medical care' requires doctors to rule
out a pulmonary embolism whenever a patient has symptoms
and risk factors that raise a reasonable suspicion that
the patient may be suffering from this condition. Untreated
pulmonary embolism often leads quickly to death. When
a patient has symptoms that raise a high level of suspicion
for pulmonary embolism, doctors must respond to the
situation as a medical emergency. A 'wait and see' approach
subjects the patient to unacceptable risk.
Doctors must respond
to the suspicion of
pulmonary embolism as a medical emergency.
Where doctors are unsure if a patient
suffers from deep vein thrombosis (DVT), the underlying
cause of pulmonary embolism, they usually need to perform
a ventilation/perfusion scan (V/Q scan), CT angiogram
or a pulmonary angiogram to definitively diagnose the
condition.2
When pulmonary embolism is not properly diagnosed, the
mortality rate rises dramatically, largely as a result
of recurrent emboli. Nearly a third of patients suffering
from pulmonary embolism will die without treatment.
Many patients die less than an hour after the onset
of symptoms. All too often, doctors fail to perform
essential tests and miss this diagnosis.
Doctors often fail
to perform essential tests
and miss the diagnosis of pulmonary embolism.
Claims based on failure to properly diagnose
pulmonary embolism fall within well established principles
of medical malpractice law.3
Many cases are based on the doctor's negligent failure
to order appropriate diagnostic tests, negligent failure
to follow proper diagnostic protocols, and negligent
failure to recognize the possibility of pulmonary embolism
based on the patient's symptoms and risk factors. Where
a physician should have a reasonable suspicion of pulmonary
embolism, the standard of medical care requires that
the physician promptly order appropriate diagnostic
tests.4
A variety of risk factors and symptoms
should give rise to a suspicion of pulmonary embolism.
Risk factors include recent surgery, a history of venous
thromboembolism (DVT), prolonged imobilization, congestive
heart failure, cancer, fracture of the pelvis, femur
or tibia, obesity, pregnancy or recent delivery, estrogen
therapy (including the use of birth control pills),
and inflammatory bowel disease.5
Over 95% of patients suffering from massive pulmonary
embolism show signs of rapid breathing (tachypnea).
Where massive pulmonary embolism leads to death, shortness
of breath (dyspnea) is present in 60% of all cases .
The failure of a physician to rule out pulmonary embolism
when confronted with breathing abnormalities such as
tachypnea and dyspnea in combination with other risk
factors and symptoms may well amount to malpractice.
Many patients have an elevated heart rate (tachycardia)
or experience a loss of consciousness (syncope). 6
In cases where physicians confuse syncope with a seizure,
they will likely fail to diagnose pulmonary embolism
. Patients often experience chest or back pain, have
abnormal breathing sounds (rales), have abnormal EKGs,
or are sweaty (diaphoretic) . 7
The Importance of Proper Treatment
When pulmonary embolism is properly diagnosed,
physicians have several treatment options which include:
anti-coagulant drugs, clot busting drugs and surgical
embolectomy. Prompt treatment with anti-coagulant (blood
thinning) drugs such as heparin can reduce the mortality
rate of the condition by about 90%.8
Because existing forms of treatment are so effective,
the vast majority of preventable deaths from pulmonary
embolism are the result of diagnostic failures. Once
pulmonary embolism or DVT is diagnosed, patients are
most often treated with high doses of heparin, which
acts immediately to prevent creation of new blood clots
and emboli. Most physicians would agree that the medical
standard of care usually requires that a physician start
full-dose heparin if he or she has a strong suspicion
of pulmonary embolism, even before the V/Q scan can
be obtained. This is because the risks of harming the
patient from heparin treatment are far outweighed by
the life threatening risk associated with pulmonary
embolism. When the patient's condition is stabilized
with heparin, patients can normally be given the oral
anticoagulant drug warfarin (Coumadin), a less powerful
blood thinner, within two to five days. Treatment with
warfarin will normally continue for weeks or months.
To ensure that the blood is adequately thinned so as
to prevent further thrombosis, physicians must perform
blood tests to monitor the patient's 'activated partial
thromboplastin time' (aPTT). If physicians fail to properly
monitor the patient's aPTT and adjust the medication
accordingly, the patient will sometimes die or suffer
injury from recurrent pulmonary embolism or DVT.
Prompt treatment
can reduce the mortality
of pulmonary embolism by 90 percent.
In cases
involving massive pulmonary embolism, more aggressive
treatment with 'clot busting' drugs or surgery may be
required. 'Clot busting' drugs are known as 'fibrinolytic
enzymes' and include streptokinase, urokinase, and tPA.
While they accelerate the rate at which clots dissolve,
they also increase the risk of stroke significantly.
Because massive pulmonary embolism is an emergent life
threatening condition, physicians who fail to give fibrinolytic
therapy immediately when a patient with pulmonary embolism
shows signs of impaired circulation or 'hemodynamic
instability' may be committing medical malpractice.
In some cases, surgical removal of an
embolism, known as an embolectomy, may be the appropriate
course of treatment. Some patients suffering from massive
pulmonary embolism cannot safely be treated with clot
busting thrombolytic drugs. These drugs may not be suitable
for patients who have suffered from stroke, recent surgery
or cancer. In contrast to the recent past, advances
in surgical technique make it possible for skilled surgeons
to perform embolectomies with relatively low risk and
high survival rates.9
Working Toward Solutions
Preventing future tragedies from occurring
can be achieved through education, action in the medical
community, and litigation. Substantially reducing the
number of preventable deaths caused by pulmonary embolism
is a goal championed by many heroes in the medical community.
Although this goal is attainable, progress in reducing
the number of preventable deaths has been elusive. Standards
of care from doctor to doctor and hospital to hospital
vary greatly. Improvements in primary medical education
and continuing medical education are of course essential.
Hospital wide initiatives to improve clinical practice
through the use of diagnostic protocols can significantly
reduce the number of needless deaths. Litigation can
serve a variety of functions that lead to solutions.
First, it can uncover problems which otherwise might
be covered up or ignored. It can punish providers of
poor care for their negligence, serve as a deterrent
to careless behavior and can provide incentives for
improvement. Finally, part of the solution must include
providing a measure of justice to victims of bad medical
practices and their families.
FOOTNOTES:
1. Fedullo, P.F., Tapson, V. F., The
Evaluation of Suspected Pulmonary Embolism, New
England Journal of Medicine, Vol. 349, pp 1247-56 (2003).
2. The PIOPED Investigators, Value
of the ventilation/perfusion scan in acute pulmonary
embolism: results of the Prospective Investigation of
Pulmonary Embolism Diagnosis (PIOPED). Journal of
the American Medical Association (JAMA), Vol. 263, pp.
2753-59 (1990).
3. Dinozzi v. Lovejoy, 20 Mass.
App. Ct. 973 (1985); Kopycinski v. Aserkoff,
410 Mass. 410 (1991); Nickerson v. Lee, 42 Mass.
App. Ct. 106 (1997).
4. Mcgrath v. Carson, ___ S.W.3d
___ (2002).
5. Fedullo, P.F., Tapson, V. F., The
Evaluation of Suspected Pulmonary Embolism, New
England Journal of Medicine, supra at 1248.
6. Feied, C.F., Pulmonary embolism.
In: Rosen and Barkin, eds, Emergency Medicine Principles
and Practice, 4th ed. 1998; 3: Chapter 111.
7. Feied, C.F., Pulmonary embolism.
In: Rosen and Barkin, eds, Emergency Medicine Principles
and Practice, 4th ed. 1998; 3: Chapter 111.
8. Carson, JL, et al., The Clinical
Clinical Course of Pulmonary Embolism, New England
Journal of Medicine, Vol 326, pp. 1240-1245 (1992);
Goldhaber SZ, Morpurgo M. Diagnosis, Treatment, and
Prevention of Pulmonary Embolism. Report of the
WHO/International Society and Federation of Cardiology
Task Force. Journal of the American Medical Association
(JAMA) 1992;268:1727-1733.
9. Aklog, L., et al., Acute Pulmonary
Embolectomy: A Contemporary Approach, Circulation,
Vol. 105, p. 1416 (2002). |
|